Oncolytic immunovirotherapy for melanoma using vesicular stomatitis virus.
about
Exploiting tumor epigenetics to improve oncolytic virotherapyOncolytic viruses as therapeutic cancer vaccinesThunder and lightning: immunotherapy and oncolytic viruses collideCancer resistance in the blind mole rat is mediated by concerted necrotic cell death mechanismIntelligent design: combination therapy with oncolytic virusesPotentiating cancer immunotherapy using an oncolytic virusPhase I/II study of oncolytic herpes simplex virus NV1020 in patients with extensively pretreated refractory colorectal cancer metastatic to the liverBig Data Offers Novel Insights for Oncolytic Virus ImmunotherapyVesicular stomatitis virus as a flexible platform for oncolytic virotherapy against cancerEmerging role of Natural killer cells in oncolytic virotherapyOncolytic viruses as anticancer vaccinesStructure of Seneca Valley Virus-001: An Oncolytic Picornavirus Representing a New GenusOncolytic parvoviruses: from basic virology to clinical applicationsHarnessing the Power of Onco-Immunotherapy with Checkpoint InhibitorsSickle Cells Abolish Melanoma Tumorigenesis in Hemoglobin SS Knockin Mice and Augment the Tumoricidal Effect of Oncolytic Virus In VivoActivation of cytotoxic and regulatory functions of NK cells by Sindbis viral vectorsIn Vitro and In Vivo Attenuation of Vesicular Stomatitis Virus (VSV) by Phosphoprotein Deletion.Potential of vesicular stomatitis virus as an oncolytic therapy for recurrent and drug-resistant ovarian cancer.Targeting a mimotope vaccine to activating Fcgamma receptors empowers dendritic cells to prime specific CD8+ T cell responses in tumor-bearing mice.Explicit targeting of transformed cells by VSV in ovarian epithelial tumor-bearing Wv mouse modelsThe in vivo therapeutic efficacy of the oncolytic adenovirus Delta24-RGD is mediated by tumor-specific immunityOncolytic Immunotherapy: Conceptual Evolution, Current Strategies, and Future PerspectivesEvaluation of an attenuated vesicular stomatitis virus vector expressing interferon-beta for use in malignant pleural mesothelioma: heterogeneity in interferon responsiveness defines potential efficacy.How Informative is the Immune Response Against Surrogate Tumor Antigens to Assess Antitumor Immunity?Vesicular stomatitis virus as a novel cancer vaccine vector to prime antitumor immunity amenable to rapid boosting with adenovirus.Recombinant vesicular stomatitis virus transduction of dendritic cells enhances their ability to prime innate and adaptive antitumor immunity.The strength of the T cell response against a surrogate tumor antigen induced by oncolytic VSV therapy does not correlate with tumor controlThe tumor-associated marker, PVRL4 (nectin-4), is the epithelial receptor for morbillivirusesInterference of CD40L-mediated tumor immunotherapy by oncolytic vesicular stomatitis virus.Maraba MG1 virus enhances natural killer cell function via conventional dendritic cells to reduce postoperative metastatic diseaseOncolytic Viruses for Cancer Therapy: Overcoming the Obstacles.Broad antigenic coverage induced by vaccination with virus-based cDNA libraries cures established tumorsEnhanced oncolytic potency of vesicular stomatitis virus through vector-mediated inhibition of NK and NKT cellsUsing virally expressed melanoma cDNA libraries to identify tumor-associated antigens that cure melanoma.Selectivity of oncolytic viral replication prevents antiviral immune response and toxicity, but does not improve antitumoral immunity.VSV oncolytic virotherapy in the B16 model depends upon intact MyD88 signaling.Adaptive antiviral immunity is a determinant of the therapeutic success of oncolytic virotherapyCharacterization of the adaptive and innate immune response to intravenous oncolytic reovirus (Dearing type 3) during a phase I clinical trial.Functional cloning of recurrence-specific antigens identifies molecular targets to treat tumor relapse.Gene therapy progress and prospects cancer: oncolytic viruses.
P2860
Q21131237-014E4297-C7D9-4CCB-BB1D-CB54A3AF47C8Q21245758-959D7AB0-4001-4B81-8244-607CFB7EDDF0Q24597894-C03F9041-EFF1-4AD4-99BA-B1CECCE07CB1Q24605044-DBABB138-8C95-42BF-B739-623A56C21578Q24628227-A5B28544-06EA-4945-A0C7-5EA2FB4F0470Q24628810-F0E484CA-3137-4072-9EAA-F9C445BC5FDEQ24633957-EE7F64D4-ED0E-4FC8-9877-31BAD314AE0FQ26767209-43CBB7B7-86F4-4BFC-8739-27E22606B6F4Q27021839-9DDE738D-91F6-4835-A06C-7DBF67F54564Q27025330-4E5457E1-1B9F-4B33-BF73-22057092F9A6Q27025600-5001A0D0-337A-4087-A410-06C64DE84D36Q27652596-FE7C7D15-13A8-4E2E-9FF6-B0BDC2A8D623Q28081685-39987329-D548-4626-8E36-551CB9C3F896Q28086999-0480D328-1CD6-4885-95CE-038682ECD7A4Q28596621-15B71A47-3D45-41A0-A7A4-0CFDA5D09ACFQ28744029-3D1B7DF4-3413-4F1F-8915-FBFC52C734B1Q30389455-9EA1D154-965C-4816-BDD3-ECA61BA35064Q33579385-A6EED820-04D9-4A49-908F-9D68718F13D8Q33584637-6C8C53BA-7149-43A8-A57B-DC695CECB338Q33620680-8766BF0C-B7A9-419B-84DB-F5EB4F2C671CQ33670728-0F0348EE-EA1E-4EEF-9A49-BD2C00E6C6B8Q33679505-529589B8-F863-451A-9777-C6AB505DCFEDQ33691838-CE21438C-E66E-41F4-86FB-13642B32E87BQ33710433-8D53BFAE-BA24-4759-888A-ADC17ADD9667Q33713083-DED29E84-E1EA-46ED-88DA-B95347899B0AQ33713903-E6BBF193-449B-41E9-BBA5-38C2A8DF073EQ33724224-1FFDD1D5-9234-4E1A-8E54-01A17561BF8FQ33820699-0D585157-468B-4F00-A8C3-D57717DCB409Q33832148-23291643-CFD6-4814-AE91-C2AF6F236A30Q33870670-F40ADE48-797B-43CD-9955-4D6BC74F85A0Q33906116-639F8F7C-517A-4473-B565-50FF4FD327FFQ33936327-DADF4FE0-CBAC-4E6C-95C6-C5029C2215A4Q34076490-D4CA49AA-B27F-48E4-AC5C-884991801AB3Q34198856-D8C92AF8-E060-4AE4-91D3-D4BAEB5153E9Q34343742-7DA78F11-A6E7-417E-9E6A-B4CA2C17547CQ34473352-D978B059-3228-41FD-862A-2B1AFE74E150Q34556927-0B524D61-FC17-414A-8297-4C37D21AF786Q34759406-D1145A77-A25A-4AC6-9A63-B91DC04F1574Q34764685-27626837-0DCA-4F56-806A-3C9988B2DE00Q34770611-B9E839DF-6635-4DCD-A3BB-BCCDEDAFCE11
P2860
Oncolytic immunovirotherapy for melanoma using vesicular stomatitis virus.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
Oncolytic immunovirotherapy for melanoma using vesicular stomatitis virus.
@en
Oncolytic immunovirotherapy for melanoma using vesicular stomatitis virus.
@nl
type
label
Oncolytic immunovirotherapy for melanoma using vesicular stomatitis virus.
@en
Oncolytic immunovirotherapy for melanoma using vesicular stomatitis virus.
@nl
prefLabel
Oncolytic immunovirotherapy for melanoma using vesicular stomatitis virus.
@en
Oncolytic immunovirotherapy for melanoma using vesicular stomatitis virus.
@nl
P2093
P1433
P1476
Oncolytic immunovirotherapy for melanoma using vesicular stomatitis virus.
@en
P2093
Glen Barber
Jill Thompson
Mikael Valdes
Phonphimon Wongthida
Richard G Vile
Rosa Maria Diaz
Timothy Kottke
P304
P356
10.1158/0008-5472.CAN-06-3974
P407
P577
2007-03-01T00:00:00Z